Clinical courses and predictors of left ventricular systolic dysfunction in systemic sclerosis: A cohort study

被引:3
作者
Werakiat, Jakrapan [1 ]
Pussadhamma, Burabha [1 ]
Mahakkanukrauh, Ajanee [1 ]
Suwannaroj, Siraphop [1 ]
Foocharoen, Chingching [1 ]
机构
[1] Khon Kaen Univ, Fac Med, Dept Med, Khon Kaen, Thailand
来源
RHEUMATOLOGY AND IMMUNOLOGY RESEARCH | 2024年 / 5卷 / 02期
关键词
systemic sclerosis; scleroderma; systolic dysfunction; myocarditis; cohort study; MYCOPHENOLATE-MOFETIL; DIASTOLIC DYSFUNCTION; SCLERODERMA; MYOCARDITIS; INVOLVEMENT; MANIFESTATIONS; CLASSIFICATION; AZATHIOPRINE; IMPROVEMENT;
D O I
10.1515/rir-2024-0014
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background and Objectives Left ventricular systolic dysfunction (LVSD) is a cardiac involvement that is the leading cause of death among patients with systemic sclerosis (SSc). We aimed to define the clinical course and predictors of LVSD among SSc patients.Methods We conducted a cohort study among adult patients with SSc who were followed up from 2013 to 2020. Semiparametric Cox regression analysis with robust clustering by cohort identification number was used to evaluate the predictors of LVSD.Results Among the 3, 987 person-years, LVSD was defined in 35 of 419 SSc patients for an incidence of 0.88 per 100 person-years. The median duration of the disease was 8.5 (interquartile range (IQR) 4.9-12.9) years. Every 1-point increase in the modified Rodnan skin score (mRSS) and salt and pepper skin were strong predictors of LVSD, with a respective adjusted hazard ratio (HR) of 1.05 and 3.17. During follow-up, 26 cases (74.3%) had unimproved LVSD. The strong predictors of the unimprovement of LVSD were every 1-point increase in mRSS (HR 1.05), every 1 mg increase in prednisolone treatment (HR 1.05), and every 1 U/L increase in creatine kinase (CK) (HR 1.001). Mycophenolate treatment was a protective factor against the unimprovement of LVSD in SSc (HR 0.15).Conclusions LVSD was frequently found in patients with diffuse cutaneous SSc, and in most cases, it remained unimproved during follow-up. High mRSS, steroid use, and high CK levels were predictors of unimproved LVSD, whereas mycophenolate treatment might prevent the progression of LVSD. Steroids should be prescribed with caution in patients with longer disease duration.
引用
收藏
页码:107 / 116
页数:10
相关论文
共 39 条
[1]  
Armstrong GP, 1996, BRIT J RHEUMATOL, V35, P983
[2]   Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens:: current questions and tentative answers in rheumatology [J].
Buttgereit, F ;
da Silva, JAP ;
Boers, M ;
Burmester, GR ;
Cutolo, M ;
Jacobs, J ;
Kirwan, J ;
Köhler, L ;
van Riel, P ;
Vischer, T ;
Bijlsma, JWJ .
ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (08) :718-722
[3]  
CARETTE S, 1985, J RHEUMATOL, V12, P997
[4]   Regional left ventricular systolic dysfunction associated with critical illness: incidence and effect on outcome [J].
Cavefors, Oscar ;
Holmqvist, Jacob ;
Bech-Hanssen, Odd ;
Einarsson, Freyr ;
Norberg, Erik ;
Lundin, Stefan ;
Omerovic, Elmir ;
Ricksten, Sven-Erik ;
Redfors, Bjorn ;
Oras, Jonatan .
ESC HEART FAILURE, 2021, 8 (06) :5415-5423
[5]   ACUTE MYOCARDITIS IN FULMINANT SYSTEMIC-SCLEROSIS [J].
CLEMSON, BS ;
MILLER, WR ;
LUCK, JC ;
FERISS, JA .
CHEST, 1992, 101 (03) :872-874
[6]  
Denton CP., 2019, European Respiratory Journal Internet, V54
[7]   Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients [J].
Eisen, HJ ;
Kobashigawa, J ;
Keogh, A ;
Bourge, R ;
Renlund, D ;
Mentzer, R ;
Alderman, E ;
Valantine, H ;
Dureau, G ;
Mancini, D ;
Mamelok, R ;
Gordon, R ;
Wang, WD ;
Mehra, M ;
Constanzo, MR ;
Hummel, M ;
Johnson, J .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2005, 24 (05) :517-525
[8]   Prognostic and functional importance of both overt and subclinical left ventricular systolic dysfunction in systemic sclerosis [J].
Fairley, Jessica L. ;
Hansen, Dylan ;
Proudman, Susanna ;
Sahhar, Joanne ;
Ngian, Gene-Siew ;
Walker, Jenny ;
Host, Lauren V. ;
La Gerche, Andre ;
Prior, David ;
Burns, Andrew ;
Morrisroe, Kathleen ;
Stevens, Wendy ;
Nikpour, Mandana ;
Ross, Laura .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2024, 66
[9]   Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure:: An endomyocardial biopsy study [J].
Fernandes, F ;
Ramires, FJA ;
Arteaga, E ;
Ianni, BM ;
Bonfá, ESDO ;
Mady, C .
JOURNAL OF CARDIAC FAILURE, 2003, 9 (04) :311-317
[10]   CARDIAC AND SKELETAL-MUSCLE DISEASE IN SYSTEMIC-SCLEROSIS (SCLERODERMA) - A HIGH-RISK ASSOCIATION [J].
FOLLANSBEE, WP ;
ZERBE, TR ;
MEDSGER, TA .
AMERICAN HEART JOURNAL, 1993, 125 (01) :194-203